How to Help Your Patients Find Paromomycin in Stock: A Provider's Guide

When you prescribe paromomycin today, you're not just making a clinical decision — you're sending your patient on a pharmacy scavenger hunt. With no generic available and only one manufacturer supplying the brand-name Humatin, your patient may call five pharmacies before finding any in stock. As the prescribing provider, you are in the best position to short-circuit that process. This guide explains how.

Why Patients Struggle to Fill This Prescription

Paromomycin is a brand-only drug since the generic manufacturer Avet Pharmaceuticals discontinued its product in September 2021. The sole available product — Humatin 250 mg capsules by Waylis Therapeutics — is not routinely stocked by most retail pharmacies due to low prescription volume and high unit cost. Patients are often turned away at the pharmacy counter entirely.

Step 1: Identify a Pharmacy Partner Before You Write the Prescription

The most efficient approach is to establish a reliable pharmacy relationship before your patients encounter this problem. Consider:

Your hospital or institution's outpatient pharmacy: Academic medical centers and hospital pharmacies are most likely to stock or be able to source Humatin quickly.

Specialty pharmacies: Many insurers route antiparasitic specialty drugs through specialty pharmacy networks. Confirm your patient's plan requirements in advance.

Local independent pharmacies: Independent pharmacists often have more flexibility to source unusual medications and may be willing to special-order Humatin if you establish an ongoing referral relationship.

Step 2: Recommend medfinder to Your Patients

For patients who need to find paromomycin without knowing which pharmacies carry it, medfinder is a paid service that calls pharmacies in the patient's area and identifies which ones can fill the prescription. The patient receives results by text message, eliminating the time-consuming phone calls on their end. This is particularly useful for paromomycin because availability varies widely by location and changes over time.

Step 3: Submit Prior Authorization Proactively

Almost every commercial insurer will require prior authorization for Humatin. Submitting it proactively — at the time of prescribing — rather than waiting for a pharmacy rejection can save 1–3 days of treatment delay. Your PA request should include:

Diagnosis code (e.g., A06.0 for acute amebic dysentery, A06.9 for amebiasis unspecified)

Stool ova and parasite or PCR test results confirming Entamoeba histolytica

Statement that paromomycin is indicated as luminal therapy following initial nitroimidazole treatment per IDSA guidelines

For pregnancy cases: note that metronidazole is contraindicated in the first trimester and paromomycin is the appropriate alternative

Step 4: Connect Patients to Cost Assistance

Even with insurance, Humatin can be expensive. Waylis Therapeutics offers two programs:

Copay savings card: Commercially insured patients may pay as little as $5 per fill. BIN 610600, PCN AS, RxGroup 373, ID 37305128031.

Patient assistance program: Uninsured patients without Medicare or TRICARE may qualify for free medication. Direct patients to humatintotalcare.com or provide the fax number for the enrollment form: 844-470-1931.

Step 5: Have a Backup Plan

For cases where Humatin cannot be sourced in a clinically acceptable timeframe, iodoquinol (650 mg TID × 20 days) is the evidence-supported backup for luminal amebiasis. For hepatic coma, rifaximin is the alternative. Brief your patient on this plan so they don't wait without options.

Summary: Provider Action Checklist

Identify a hospital, specialty, or independent pharmacy that can source Humatin

Send prior authorization simultaneously with writing the prescription

Provide patient with Humatin TotalCare copay card information

Recommend medfinder if the patient cannot locate the medication independently

Have iodoquinol or rifaximin ready as backup depending on indication

See also our full Paromomycin Shortage Provider Guide for clinical alternatives and PA strategies.